Clinical trials: Precision Treatment
Patent Ductus Arteriosus, Preterm
Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even…
- Trial name
- MIPD-PDA (NCT07143201)
- Testing
- Standard Dose - Ibuprofen oral suspension, Precision Dose - Ibuprofen oral suspension
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Hamilton Health Sciences Corporation
Epilepsy
Precision Medicine in the Treatment of Epilepsy
Primary objectives: The purpose of this study is to identify single and composite biomarkers (from neuroimaging, electrophysiological, and non-imaging biological measures), clinical measures (from cognitive, psychometric, and…
- Trial name
- BDE (NCT05450822)
- Testing
- Levetiracetam, Levetiracetam Tablets, Lamotrigine tablet
- Where
- Denmark
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Gitte Moos Knudsen
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
ARDS, Human, Covid19
Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset
The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world.
- Trial name
- NorthCARDS (NCT04729075)
- Testing
- ARDS and COVID19 treatments
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- Northwell Health
Major Depressive Disorder
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Major depressive disorder (MDD) is the most common psychiatric disease worldwide with a huge socio-economic impact. Pharmacotherapy represents the first-line treatment choice; however, only about one third of patients respond to…
- Trial name
- PROMPT (NCT05537558)
- Testing
- Antidepressant
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Muenster
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Bladder Cancer
The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
This study was a prospective, multicenter observational clinical study, A total of 150 patients with bladder malignant tumor who was admitted to the urology department of each center for treatment and underwent electric resection…
- Trial name
- NCT05096533
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pharmacokinetics, Area Under Curve
Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment
This is a prospective observational study of MIPD in clinical practice for paediatric kidney transplant patients using tacrolimus and mycophenolic acid in Radboudumc.
- Conditions
- Pharmacokinetics, Area Under Curve, Tacrolimus, Immunosuppressive Agents
- Trial name
- MISSION (NCT06095895)
- Testing
- venipuncture
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Radboud University Medical Center
Childhood Leukemia
Advanced Translational Research on Childhood Leukemia
Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of <50%, which is unlikely to be boosted by…
- Trial name
- NCT04478006
- Testing
- RNA-seq, whole exon sequencing, Cytogenetics test
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Knee Osteoarthritis
The Right Treatment for the Right Patient at the Right Time. A Study Following 5,000 Patients With Knee Osteoarthritis
The treatment that patients with knee OA are offered varies largely. There is a need for more evidence-based individualized guidance to treatment choice for knee osteoarthritis.
- Trial name
- TREATright (NCT03746184)
- Testing
- Treatment course
- Where
- Denmark
- Volunteers
- 3,507 people
- Sponsor
- Hvidovre University Hospital
Oncology
A Patient-Centric Platform Trial for Precision Oncology
XCELSIOR is a non-interventional data registry. Information about treatments, treatment decisions and rationale, and patient outcomes including safety and effectiveness of anti-cancer therapy and associated supportive care will…
- Trial name
- XCELSIOR (NCT03793088)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- xCures
Sepsis
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments.
- Trial name
- PALETTE (NCT06381661)
- Testing
- Tocilizumab, Baricitinib, Anakinra
- Where
- 19 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autism Spectrum Disorder
Precision TMS Treatment Guided by Personalized Brain Functional Sectors (pBFS) for ASD
This study will evaluate the efficacy and safety of pBFS-guided TMS treatment for the core symptom in autism spectrum disorder children, adolescents and young adults.
- Trial name
- NCT05890846
- Testing
- active iTBS, traditional 1on1 course
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Changping Laboratory
Leukemia, Leukemia, Acute
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase…
- Conditions
- Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma, Leukemia, Lymphoblastic
- Trial name
- NCT03564704
- Testing
- Dexamethasone, vincristine, Cyclophosphamide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Neuromuscular Diseases, Eye Diseases
Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes
PARADIGM study, funded by the PNRR research grant, will focus on Eye Diseases (ED) and Neuro-Muscular Diseases (NMD) as groups of genetically heterogeneous diseases which are extensively studied by the Partners partecipating in…
- Conditions
- Neuromuscular Diseases, Eye Diseases, Genetic Disease
- Trial name
- NCT06775561
- Testing
- PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a…
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- TAPUR (NCT02693535)
- Testing
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Where
- 181 sites in United States, Puerto Rico
- Volunteers
- 4,200 people
- Sponsor
- American Society of Clinical Oncology
Rheumatoid Arthritis
PRECISion medicinE Across the Disease Continuum to Prevent and Treat Rheumatoid Arthritis
The study will recruit patients referred to the Rheumatology Out-patient departments. Patients will be recruited to the study or control groups (healthy or disease controls who will be age and sex-matched) as needed.
- Trial name
- PRECISE-RA (NCT04482335)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Primary Dystonia, Transcranial Magnetic Stimulation
Precision-targeted Transcranial Magnetic Stimulation in the Treatment of Primary Dystonia
In this scheme, TMS treatment of Primary dystonia is planned by precise magnetic resonance positioning.
- Trial name
- NCT04727177
- Testing
- Transcranial magnetic stimulation
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Depression / Major Depressive Disorder
Biomarkers and Pharmacogenomics for Precision Depression Therapy
Background: The clinical management of major depressive disorder (MDD) is hampered by the lack of objective biomarkers and high inter-individual variability in drug response, with conventional antidepressants achieving only a 50%…
- Trial name
- NCT07738497
- Testing
- Pharmacogenomic Testing, Antidepressant Agents
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine